Tag: AMD

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- GraniteShares has announced it will execute a reverse share split for the GraniteShares 2x Short COIN (the “Fund”). The total market value of the shares outstanding will not be affected as a result of the reverse split.